

FORM PTO-1449				U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. P28506	Application No. 10/550,013
<p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)</p> <p style="text-align: center;">APR 07 2008 O.I.P. INFORMATION DISCLOSURE STATEMENT U.S. Patent and Trademark Office</p>				Applicant Rudolf FAHRIG et al.		
				Filing Date September 23, 2005		Group Unknown
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	IF APPROPRIATE
M.C.H	6 5 8 9 9 4 1	07/08/03	FAHRIG et al.	—	—	
M.C.H	2004 0 1 2 7 4 5 4	07/01/04	FAHRIG et al.	—	—	
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
M.C.H	0 8 0 6 9 5 6	08/28/02	E.P.O	—	—	
	01 / 0 7 0 8 8	02/01/01	W.I.P.O	—	—	
	96 / 2 3 5 0 6	08/08/96	W.I.P.O	—	—	
M.C.H	02 / 0 6 7 9 5 1	09/06/02	W.I.P.O	—	—	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
M.C.H	1	E. de Clercq, "Potential of Bromovinyldeoxyuridine in Anticancer Chemotherapy," <i>Anticancer Research</i> , vol. 6, no. 4, July 1986, pp. 549-556.				
	2	R. Fahrig et al., "Prevention of adriamycin-induced mdr1 gene amplification and expression in mouse leukemia cells by simultaneous treatment with the anti-recombinogen bromovinyldeoxyuridine," <i>Anti-Cancer Drug Design</i> (2000), 15(5), pp. 307-312 (incorrectly dated 2001 in the International Search Report).				
	3	M. Iigo et al., "Effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine on Life-Span and 5-Fluorouracil metabolism in Mice with Hepatic Metastases," <i>Euro. J. Cancer</i> , vol. 26, no. 10, 1990, pp. 1089-1092.				
	4	B. Degreve et al., "Selection of HSV-1 TK Gene-Transfected murine Mammary Carcinoma Cells Resistant to (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and ganciclovir (GCV)" <i>Gene Therapy</i> (2000), 7(18), pp. 1543-52.				
	5	J. Balzarini, "Increased Sensitivity of Thymine Kinase Deficient (TK-) Tumor Cell Lines to the Cell Growth Inhibitory Effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and Related Compounds," <i>Anticancer Research</i> , vol. 6, no. 5, 1986, pp. 1077-1084.				
	6	S. Pancheva, "Methotrexate Potentiates Anti-Herpes Simplex Virus Type 1 Activity of E-5-(2-bromovinyl)-2'-deoxyuridine," <i>Acta viologica</i> , vol. 39, no. 2, 1995, pp. 117-119.				
	7	J. Kerr et al., "Apoptosis: A Basic Biological Phenomenon with Wide-Ranging Implications in Tissue Kinetics," <i>Br. J. Cancer</i> , (1972) 26, pp. 239-257.				
	8	R. Fahrig et al., "Induction or suppression of SV40 amplification by genotoxic carcinogens, non-genotoxic carcinogens, or tumor promoters," <i>Mutation Research</i> 356 (1996) 217-224.				
	9	R. Fahrig, "Anti-recombinogenic and convertible co-mutagenic effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and other 5-substituted nucleoside analogs in <i>S. cerevisiae</i> MP1," <i>Mutation Research</i> 372 (1996) 133-39.				
M.C.H	10	Hodnick et al., "Measurement of Dicumarol-Sensitive NADPH:(Menadione-Cytochrome c) Oxidoreductase Activity Results in an Artifactual Assay of DT-Diaphorase in Cell Sonicates," <i>Anal. Biochem.</i> 252(1), 1997, 165-168.				
EXAMINER			DATE CONSIDERED <u>6/23/07</u>			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						